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Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global
Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source
(NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban
versus aspirin in patients with recent ESUS. Aims: We aimed to describe the base-
line characteristics of this large ESUS cohort to explore relationships among key
subgroups. Methods: We enrolled 7213 patients at 459 sites in 31 countries. Prespecified
subgroups for primary safety and efficacy analyses included age, sex, race, global
region, stroke or transient ischemic attack prior to qualifying event, time to ran-
domization, hypertension, and diabetes mellitus. Results: Mean age was 66.9 ± 9.8
years; 24% were under 60 years. Older patients had more hypertension, coro-
nary disease, and cancer. Strokes in older subjects were more frequently cortical
and accompanied by radiographic evidence of prior infarction. Women com-
prised 38% of participants and were older than men. Patients from East Asia were
oldest whereas those from Latin America were youngest. Patients in the Ameri-
cas more frequently were on aspirin prior to the qualifying stroke. Acute cortical
infarction was more common in the United States, Canada, and Western Europe,
whereas prior radiographic infarctions were most common in East Asia. Approx-
imately forty-five percent of subjects were enrolled within 30 days of the qualifying
stroke, with earliest enrollments in Asia and Eastern Europe. Conclusions: NAVIGATE-
ESUS is the largest randomized trial comparing antithrombotic strategies for secondary
stroke prevention in patients with ESUS. The study population encompasses a
broad array of patients across multiple continents and these subgroups provide
ample opportunities for future research. Key Words: Stroke—cryptogenic
stroke—cerebral embolism—Embolic Stroke of Undetermined Source (ESUS)—stroke
prevention—rivaroxaban—aspirin—randomized trial.
© 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Introduction
Embolic stroke of undetermined source (ESUS) is a subset
of cryptogenic stroke, and a diagnostic label proposed
for an ischemic stroke that occurs without an identifi-
able and specifically treatable underlying stroke etiology,
including greater than 50% stenosis in a large proximal
artery in the territory of ischemia, atrial fibrillation or other
major-risk cardioembolic source, lacunar (small vessel oc-
clusive) disease, or identified uncommon cause.1 ESUS
accounts for 15% to 30% of all ischemic strokes.2 A wide
range of potential cardiac, arterial, paradoxical, and he-
matological sources have been proposed that might be
amenable to treatment with an anticoagulant.1,3,4 The New
Approach Rivaroxaban Inhibition of Factor Xa in a Global
trial vs. ASA to Prevent Embolism in Embolic Stroke of
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Undetermined Source (NAVIGATE-ESUS) trial is an in-
ternational randomized phase-III trial comparing
rivaroxaban with aspirin in patients with recent ESUS.
The design of the trial has previously been reported,5 en-
rollment of 7213 subjects has recently been completed,
and participant features are reported here.
Although the NAVIGATE-ESUS participants share a
common diagnosis of ESUS, they likely vary with respect
to the underlying potential embolic sources,6 and there-
fore subgroup analyses may be especially important.7,8
Subgroup analysis in clinical trials is often performed for
2 key purposes. One major goal is to explore the con-
sistency of a treatment effect among different
subpopulations that are defined at baseline. The other is
to investigate whether there are specific groups that are
more or less likely to receive benefit or harm from the
treatment. Together, these assessments of both homoge-
neity and heterogeneity can yield valuable information
for clinicians and future research, but these analyses must
be interpreted cautiously, mitigated by reduced statisti-
cal power and the play of chance.9 Subgroup analysis can
also help identify populations at greatest risk of a re-
current event. Clinical characteristics of selected subgroups
pre-specified in the NAVIGATE ESUS trial statistical anal-
ysis plan are provided.
Methods
NAVIGATE ESUS Study Design
The design of NAVIGATE ESUS (clinicaltrials.gov.
NCT02313909) has previously been published.5 In brief,
it is an international, double-blinded, randomized phase-
III superiority trial comparing rivaroxaban 15 mg once
daily (immediate-release, film-coated tablets) with aspirin
(enteric-coated) 100 mg once daily, both to be taken with
food, in patients with recent ESUS. Target enrollment was
approximately 7000, and the study was designed to con-
tinue until at least 450 primary events have occurred. Key
eligibility criteria for NAVIGATE ESUS are summarized
in the Appendix (Supplementary Table S1). The primary
efficacy outcome is time to recurrent stroke, comprising
ischemic, hemorrhagic, and undefined stroke, including
transient ischemic attacks (TIAs) with positive
neuroimaging10 or systemic embolism. The primary safety
outcome is major bleeding as defined by the criteria of
the International Society of Thrombosis and Haemostasis.11
The main efficacy and safety results will be available in
2018.
Baseline Characteristics and Subgroup Analyses
Baseline characteristics collected in the trial include de-
mographic features, medical history, qualifying stroke
information, and baseline functional and cognitive status.
Prespecified participant subgroup analyses for which the
treatment effects will be presented in the main results
publication were chosen for presentation here, in accor-
dance with the statistical analysis plan. These included
the following, based on the data collected at the time of
randomization: age, sex, race, global region, stroke or TIA
prior to qualifying event, time from qualifying stroke to
randomization, hypertension, and diabetes mellitus.
Statistical Analysis
We describe the features of all subjects and compare
the baseline characteristics for selected prespecified sub-
groups. Descriptive statistics use mean ± standard deviation,
median (interquartile range [IQR]), or proportion as ap-
propriate. Univariate comparisons were made using t-tests
for continuous variables and chi-square tests for cate-
gorical variables, and we present nominal 2-sided P values.
For comparisons within subgroups, we consider only P
values less than .01 to be significant to account for the
multiple comparisons.
Results
A total of 7213 subjects were randomized in the NAV-
IGATE ESUS trial between December 24, 2014 and
September 20, 2017. The major baseline characteristics for
the entire study population are summarized in Table 1.
The mean age was 66.9 ± 9.8 years, and 62% were men.
Median baseline National Institutes of Health Stroke Scale
score was 1 (IQR 0, 2) and was less than or equal to 5
in 96% of patients. All subjects had extracranial vascu-
lar imaging, echocardiography, and initial cardiac rhythm
monitoring as required by protocol, and 78% had intra-
cranial vascular imaging. Forty-three percent of patients
were enrolled from Western Europe (Figure 1). Charac-
teristics of prespecified selected subgroups are summarized
in Tables 2-4 and the Supplementary Tables. Key differ-
ences among subgroups are described below. Of note, only
7% of participants had a history of coronary artery disease
due to protocol stipulation excluding patients who require
single or dual antiplatelet therapy.
Age
As summarized in Table 2, 24% of patients were under
60 and 21% were older than 75 years. Older subjects were
more likely to be women, of white race, and had lower
weight and BMI values as well as lower estimated glo-
merular filtration rates. Older subjects had a greater burden
of hypertension, coronary artery disease, cancer, but there
were fewer smokers and less diabetes. Cognitive func-
tion as assessed by the Montreal Cognitive Assessment
(MoCA) was more impaired with increasing age. Aspirin
use prior to the qualifying stroke was more common with
increasing age. The qualifying strokes in older subjects
more frequently involved the cerebral cortex and were
more often accompanied by evidence of prior or chronic
infarcts observed on neuroimaging.
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Sex
As shown in Table 3, compared with men, the 39% of
subjects who were women were older, more likely to be
white and less likely to be Asian. Women had lower weight
but slightly greater BMI than men. Women had mod-
estly more hypertension but were less likely to be current
smokers. Women were more commonly treated with acute
thrombolysis or endovascular therapy.
Region
As summarized in Table 4, patients enrolled in Western
Europe tended to be the oldest. Smoking was more
common in Eastern Europe and East Asia. Patients in the
Americas were more likely to be on aspirin prior to the
qualifying stroke than those from Europe and East Asia.
Patients were less likely to be treated with thrombolysis
for the qualifying stroke in Latin America and East Asia.
Acute cortical infarction was more common in North
America and Western Europe, whereas chronic infarc-
tions in addition to the index stroke were most commonly
observed in East Asia.
Race
The majority of subjects were white (72%) or Asian (20%).
Variability in baseline characteristics by race is shown in
Supplementary Table S2, with notably lower BMI values
among Asians and more current tobacco use. Asians also
appeared more likely to have subcortical infarctions, more
chronic infarctions, and suffered less disability from their
strokes (mRS 0-1). Blacks were enrolled mainly in the
Americas and had the highest prevalence of hypertension.
Hypertension
A history of hypertension was reported in 77% of
subjects, and was associated with older age and the
presence of diabetes and coronary artery disease, as
shown in Supplementary Table S3. Patients with hyper-
tension were more likely to be taking aspirin prior to
the qualifying stroke, had more evidence of chronic
radiographic infarction, and mildly lower MoCA
scores.
Diabetes mellitus
Diabetes mellitus was present in 25% of subjects at en-
rollment and characteristics are summarized in
Supplementary Table S4. Patients with diabetes were
younger, had greater BMI values, and were more likely
to have hypertension, coronary disease, prior stroke as
well as chronic radiographic infarction, and mildly lower
MoCA scores. Aspirin use prior to the index stroke was
more common and thrombolysis use less common in pa-
tients with diabetes.
Stroke or TIA prior to index event
As shown in Supplementary Table S5, 17% of sub-
jects had a prior clinical stroke or TIA. These patients
were similar with respect to demographic features,
but had a greater burden of coronary artery disease.
Aspirin use prior to the index stroke and chronic
infarcts on imaging were more than twice as common
in this group, and they had slightly lower MoCA
scores.
Figure 1. Enrollment by global region in the NAVIGATE-ESUS trial. Abbreviation: NAVIGATE-ESUS, New Approach Rivaroxaban Inhibition of Factor
Xa in a Global trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source.
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Table 1. Baseline characteristics of the complete NAVIGATE-ESUS study population
Characteristic N with Data Summary (N = 7214)
Age, years (mean ± s.d.) 7213 66.9 ± 9.8
Age<60 years 7213 1716 (24)
Male sex 7213 4437 (62)
Race:
White only 7213 5219 (72)
Black only 7213 111 (2)
East Asian only 7213 1414 (20)
Others (includes not reported/multiracial) 7213 470 (7)
BMI, kg/m2 (mean ± s.d.) 7182 27.2 ± 5.0
<25 kg/m2 7182 2505 (35)
≥25–<30 kg/m2 7182 2970 (41)
≥30 kg/m2 7182 1708 (24)
<30 kg/m2 7182 5475 (76)
≥30 kg/m2 7182 1708 (24)
Weight, kg (mean ± s.d.) 7189 76.2 ± 16.5
<70 kg 7189 2535 (35)
70–90 kg 7189 3479 (48)
>90 kg 7189 1176 (16)
<50 kg 7189 199 (3)
50–100 kg 7189 6467 (90)
>100 kg 7189 524 (7)
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 7209 78.6 ± 20.6
<50 mL/min 7209 419 (6)
50–80 mL/min 7209 3531 (49)
>80 mL/min 7209 3260 (45)
Medical history:
Hypertension 7213 5586 (77)
Diabetes mellitus 7213 1805 (25)
Current tobacco use 7212 1484 (21)
Coronary artery disease 7213 473 (7)
Heart failure 7213 238 (3)
Cancer 7213 620 (9)
Bioprosthetic heart valve 7213 21 (0)
Prior stroke or TIA 7213 1263 (18)
Global region:
U.S.A. and Canada 7213 918 (13)
Latin America 7213 746 (10)
Western Europe 7213 3081 (43)
Eastern Europe 7213 1119 (16)
East Asia 7213 1350 (19)
Qualifying stroke:
Clinical TIA with imaging-confirmed infarction as qualifying event: 7213 521 (7)
Arterial territory of qualifying stroke:
Anterior circulation 7213 5187 (72)
Posterior circulation 7213 2269 (31)
Location of qualifying stroke:
Single Location:
Cerebral hemisphere with cortical involvement 7213 4036 (56)
Cerebral hemisphere, subcortical only 7213 1518 (21)
Brainstem only 7213 331 (5)
Cerebellum only 7213 562 (8)
Multiple Locations: 7213 762 (11)
Chronic infarct on imaging (in addition to index stroke) 7212 2350 (33)
Aspirin use prior to qualifying stroke 7213 1247 (17)
Statin use prior to randomization 7213 4425 (61)
Treated with intravenous tPA for qualifying stroke 7213 1255 (17)
Treated with endovascular intervention for qualifying stroke 7213 300 (4)
NIHSS score at randomization (median, IQR) 7209 1.0 (0.0, 2.0)
NIHSS score ≤5 7209 6927 (96)
Modified Rankin Scale (mRS) at randomization:
mRS 0 or 1 7212 4670 (65)
mRS 2 7212 1673 (23)
mRS ≥3 7212 870 (12)
MoCA score at randomization (median, IQR) 6531 25.0 (21.0, 27.0)
Time from qualifying stroke to randomization, days (median, IQR) 7213 37.0 (14.0, 88.0)
Extracranial vascular imaging completed:
CTA 7211 2743 (38)
MRA 7212 2380 (33)
Carotid ultrasound 7212 4553 (63)
Conventional angiography 5583 121 (2)
Intracranial vascular imaging completed:
CTA but not MRA or Transcranial Doppler 7213 2586 (36)
MRA but not Transcranial Doppler 7213 2201 (31)
Transcranial Doppler 7213 857 (12)
None 7213 1570 (22)
Transthoracic echocardiography: 7213 6885 (95)
Left atrial diameter, cm (mean ± s.d.) 4009 3.8 ± 1.4
Left ventricular ejection fraction, % (mean ± s.d.) 5761 62.3 ± 8.1
Transesophageal echocardiography 7211 1382 (19)
Patent foramen ovale present 1382 372 (27)
Duration of cardiac rhythm monitoring ≥48 hours 7207 2438 (34)
Abbreviations: BMI, body mass index; CTA, computed tomographic angiography; IQR, interquartile range; MoCA, Montreal Cognitive Assessment; MRA, magenetic resonance angiography;
NAVIGATE-ESUS, New Approach Rivaroxaban Inhibition of Factor Xa in a Global trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source; NIHSS, National Institutes of
Health Stroke Scale; SD, standard deviation; TIA, transient ischemic attack; tPA, tissue plasminogen activator.
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(N = 1485) P trend^
Age, years (mean ± s.d.) 54.1 ± 4.5 67.4 ± 4.4 80.5 ± 3.7
Male sex 1211 (71) 2525 (63) 701 (47) <.001
Race:
White only 1143 (67) 2933 (73) 1143 (77)
Black only 43 (3) 58 (1) 10 (1)
East Asian only 410 (24) 764 (19) 240 (16)
Others (includes not reported/multiracial) 120 (7) 258 (6) 92 (6) <.001
BMI, kg/m2 (mean ± s.d.) 27.9 ± 5.4 27.3 ± 5.0 26.3 ± 4.5 <.001
Weight, kg (mean ± s.d.) 80.5 ± 17.3 76.6 ± 16.2 69.9 ± 14.5 <.001
Estimated glomerular filtration rate (eGFR), mL/min
per 1.73 m2
88.1 ± 21.0 78.7 ± 19.3 67.5 ± 17.4 <.001
Medical history:
Hypertension 1344 (78) 3005 (75) 1237 (83) 0.002
Diabetes mellitus 456 (27) 1014 (25) 335 (23) 0.01
Current tobacco use 648 (38) 760 (19) 76 (5) <.001
Coronary artery disease 79 (5) 254 (6) 140 (9) <.001
Heart failure 65 (4) 113 (3) 60 (4) 0.80
Cancer 43 (3) 358 (9) 219 (15) <.001
Bioprosthetic heart valve 3 (0) 12 (0) 6 (0) 0.23
Prior stroke or TIA 331 (19) 625 (16) 307 (21) 0.44
Global region:
U.S.A. and Canada 251 (15) 502 (13) 165 (11)
Latin America 177 (10) 429 (11) 140 (9)
Western Europe 595 (35) 1672 (42) 814 (55)
Eastern Europe 306 (18) 681 (17) 132 (9)
East Asia 387 (23) 729 (18) 234 (16) <.001
Qualifying stroke:
Clinical TIA with imaging-confirmed infarction as
qualifying event:
96 (6) 311 (8) 114 (8) 0.02
Arterial territory of qualifying stroke:
Anterior circulation 1224 (71) 2868 (71) 1095 (74) 0.14
Posterior circulation 538 (31) 1280 (32) 451 (30) 0.58
Location of qualifying stroke:
Single Location:
Cerebral hemisphere with cortical involvement 828 (48) 2276 (57) 932 (63) <.001
Cerebral hemisphere, subcortical only 461 (27) 839 (21) 218 (15) <.001
Brainstem only 95 (6) 191 (5) 45 (3) <.001
Cerebellum only 148 (9) 302 (8) 112 (8) 0.23
Multiple Locations: 184 (11) 403 (10) 175 (12) 0.38
Chronic infarct on imaging (in addition to index stroke) 528 (31) 1278 (32) 544 (37) <.001
Aspirin use prior to qualifying stroke 216 (13) 673 (17) 358 (24) <.001
Treated with intravenous tPA for qualifying stroke 271 (16) 736 (18) 248 (17) 0.42
Treated with endovascular intervention for qualifying stroke 69 (4) 174 (4) 57 (4) 0.83
NIHSS score at randomization (median, IQR) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) <.001
Modified Rankin Scale (mRS) at randomization:
mRS 0 or 1 1091 (64) 2704 (67) 875 (59)
mRS 2 436 (25) 877 (22) 360 (24)
mRS ≥3 189 (11) 431 (11) 250 (17) <.001
MoCA score at randomization (median, IQR) 26.0 (22.0, 28.0) 25.0 (21.0, 27.0) 22.0 (18.0, 26.0) <.001
Time from qualifying stroke to randomization, days
(median, IQR)
35.0 (14.0, 87.5) 37.0 (15.0, 90.0) 36.0 (14.0, 86.0) 0.42
Abbreviations: BMI, body mass index; IQR, interquartile range; MoCA, Montreal Cognitive Assessment; NIHSS, National Institutes of
Health Stroke Scale; SD, standard deviation; TIA, transient ischemic attack; tPA, tissue plasminogen activator.
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(N = 2777) P value^
Age, years (mean ± s.d.) 65.6 ± 9.4 69.1 ± 10.0 <.001
Age<60 years 1211 (27) 505 (18) <.001
Race:
White only 3107 (70) 2112 (76)
Black only 64 (1) 47 (2)
East Asian only 980 (22) 434 (16)
Others (includes not reported/multiracial) 286 (6) 184 (7) <.001
BMI, kg/m2 (mean ± s.d.) 27.1 ± 4.6 27.5 ± 5.6 <.001
Weight, kg (mean ± s.d.) 80.2 ± 15.7 69.7 ± 15.6 <.001
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 80.7 ± 20.7 75.4 ± 19.9 <.001
Medical history:
Hypertension 3346 (75) 2240 (81) <.001
Diabetes mellitus 1156 (26) 649 (23) 0.01
Current tobacco use 1159 (26) 325 (12) <.001
Coronary artery disease 320 (7) 153 (6) 0.004
Heart failure 155 (3) 83 (3) 0.24
Cancer 366 (8) 254 (9) 0.19
Bioprosthetic heart valve 15 (0) 6 (0) 0.35
Prior stroke or TIA 735 (17) 528 (19) 0.008
Global region:
U.S.A. and Canada 533 (12) 385 (14)
Latin America 417 (9) 329 (12)
Western Europe 1869 (42) 1212 (44)
Eastern Europe 687 (15) 432 (16)
East Asia 931 (21) 419 (15) <.001
Qualifying stroke:
Clinical TIA with imaging-confirmed infarction as qualifying event: 331 (7) 190 (7) 0.32
Arterial territory of qualifying stroke:
Anterior circulation 3135 (71) 2052 (74) 0.003
Posterior circulation 1461 (33) 808 (29) <.001
Location of qualifying stroke:
Single Location:
Cerebral hemisphere with cortical involvement 2449 (55) 1587 (57) 0.10
Cerebral hemisphere, subcortical only 925 (21) 593 (21) 0.61
Brainstem only 213 (5) 118 (4) 0.28
Cerebellum only 354 (8) 208 (7) 0.45
Multiple Locations: 494 (11) 268 (10) 0.05
Chronic infarct on imaging (in addition to index stroke) 1481 (33) 869 (31) 0.06
Aspirin use prior to qualifying stroke 745 (17) 502 (18) 0.16
Treated with intravenous tPA for qualifying stroke 730 (16) 525 (19) 0.007
Treated with endovascular intervention for qualifying stroke 148 (3) 152 (5) <.001
NIHSS score at randomization (median, IQR) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 0.83
Modified Rankin Scale (mRS) at randomization:
mRS 0 or 1 2951 (67) 1719 (62)
mRS 2 994 (22) 679 (24)
mRS ≥3 492 (11) 378 (14) <.001
MoCA score at randomization (median, IQR) 25.0 (21.0, 27.0) 24.0 (20.0, 27.0) <.001
Time from qualifying stroke to randomization, days (median, IQR) 36.0 (14.0, 90.0) 37.0 (15.0, 85.0) 0.76
Abbreviations: BMI, body mass index; IQR, interquartile range; MoCA, Montreal Cognitive Assessment; NIHSS, National Institutes of
Health Stroke Scale; SD, standard deviation; TIA, transient ischemic attack; tPA, tissue plasminogen activator.
NAVIGATE ESUS TRIAL BASELINE CHARACTERISTICS 1679











(N = 1350) P value^
Age, years (mean ± s.d.) 66.2 ± 9.8 66.4 ± 10.0 68.7 ± 9.8 64.7 ± 8.5 65.6 ± 10.1 <.001
Age<60 years 251 (27) 177 (24) 595 (19) 306 (27) 387 (29) <.001
Male sex 533 (58) 417 (56) 1869 (61) 687 (61) 931 (69) <.001
Race:
White only 783 (85) 605 (81) 2714 (88) 1117 (100) 0 (0)
Black only 59 (6) 29 (4) 22 (1) 1 (0) 0 (0)
East Asian only 42 (5) 2 (0) 23 (1) 0 (0) 1347 (100)
Others (includes not reported/multiracial) 34 (4) 110 (15) 322 (10) 1 (0) 3 (0) <.001
BMI, kg/m2 (mean ± s.d.) 29.3 ± 6.4 28.1 ± 4.6 27.5 ± 4.8 28.3 ± 4.5 23.8 ± 3.2 <.001
Weight, kg (mean ± s.d.) 83.4 ± 19.2 74.5 ± 14.5 78.1 ± 15.7 81.1 ± 14.6 63.7 ± 11.2 <.001
Estimated glomerular filtration rate (eGFR), mL/min per 1.73 m2 73.3 ± 17.8 80.9 ± 22.0 77.5 ± 19.2 78.6 ± 20.1 83.5 ± 23.4 <.001
Medical history:
Hypertension 672 (73) 621 (83) 2334 (76) 995 (89) 964 (71) <.001
Diabetes mellitus 220 (24) 230 (31) 690 (22) 305 (27) 360 (27) <.001
Current tobacco use 154 (17) 96 (13) 567 (18) 275 (25) 392 (29) <.001
Coronary artery disease 114 (12) 27 (4) 158 (5) 114 (10) 60 (4) <.001
Heart failure 30 (3) 16 (2) 81 (3) 102 (9) 9 (1) <.001
Cancer 120 (13) 41 (5) 308 (10) 49 (4) 102 (8) <.001
Bioprosthetic heart valve 6 (1) 0 (0) 11 (0) 2 (0) 2 (0) 0.10
Prior stroke or TIA 215 (23) 136 (18) 508 (16) 153 (14) 251 (19) <.001
Qualifying stroke:
Clinical TIA with imaging-confirmed infarction as qualifying event: 71 (8) 41 (5) 289 (9) 30 (3) 90 (7) <.001
Arterial territory of qualifying stroke:
Anterior circulation 657 (72) 525 (70) 2229 (72) 789 (71) 987 (73) 0.51
Posterior circulation 303 (33) 239 (32) 915 (30) 339 (30) 473 (35) 0.006
Location of qualifying stroke:
Single Location:
Cerebral hemisphere with cortical involvement 595 (65) 417 (56) 1973 (64) 518 (46) 533 (39) <.001
Cerebral hemisphere, subcortical only 124 (14) 183 (25) 449 (15) 364 (33) 398 (29) <.001
Brainstem only 19 (2) 56 (8) 99 (3) 76 (7) 81 (6) <.001
Cerebellum only 70 (8) 51 (7) 247 (8) 92 (8) 102 (8) 0.81
Multiple Locations: 109 (12) 39 (5) 309 (10) 69 (6) 236 (17) <.001
Chronic infarct on imaging (in addition to index stroke) 261 (28) 253 (34) 836 (27) 414 (37) 586 (43) <.001
Aspirin use prior to qualifying stroke 196 (21) 168 (23) 551 (18) 185 (17) 147 (11) <.001
Treated with intravenous tPA for qualifying stroke 191 (21) 57 (8) 684 (22) 205 (18) 118 (9) <.001
Treated with endovascular intervention for qualifying stroke 69 (8) 7 (1) 159 (5) 20 (2) 45 (3) <.001
NIHSS score at randomization (median, IQR) 0.0 (0.0, 1.0) 2.0 (1.0, 4.0) 0.0 (0.0, 2.0) 2.0 (0.0, 3.0) 1.0 (0.0, 2.0) <.001
Modified Rankin Scale (mRS) at randomization:
mRS 0 or 1 636 (69) 411 (55) 2051 (67) 633 (57) 939 (70)
mRS 2 207 (23) 218 (29) 682 (22) 308 (28) 258 (19)
mRS ≥3 75 (8) 117 (16) 347 (11) 178 (16) 153 (11) <.001
MoCA score at randomization (median, IQR) 26.0 (23.0, 28.0) 22.0 (17.0, 25.5) 25.0 (21.0, 27.0) 25.0 (22.0, 27.0) 23.0 (19.0, 26.0) <.001
Time from qualifying stroke to randomization, days (median, IQR) 70.0 (41.0, 123.0) 54.0 (31.0, 102.0) 42.0 (14.0, 100.0) 22.0 (13.0, 57.0) 18.0 (11.0, 37.0) <.001
Abbreviations: BMI, body mass index; IQR, interquartile range; MoCA, Montreal Cognitive Assessment; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TIA, transient ischemic













Time from qualifying stroke to randomization
As indicated in Supplementary Table S6, 45% of sub-
jects were enrolled within 30 days of the qualifying stroke,
31% between 30 and 90 days, and 24% between 3 and 6
months. Patients in East Asia and Eastern Europe were
enrolled earlier than in other regions.
Discussion
NAVIGATE ESUS is the largest randomized trial com-
paring antithrombotic therapeutic strategies for secondary
stroke prevention in patients with ESUS. The study pop-
ulation encompasses a wide spectrum of patients across
multiple continents. Moreover, the population is similar
to published smaller cohorts of patients with crypto-
genic stroke or ESUS,2,12-15 supporting the external validity
and generalizability of the ESUS concept and its imple-
mentation in this trial.
The hypothesis of the NAVIGATE-ESUS trial is that
rivaroxaban would be associated with a substantially lower
risk of recurrent embolic events without a clinically un-
acceptable increase of major hemorrhages relative to aspirin,
with relatively consistent treatment effects across the sub-
groups described here. However, higher event rates would
be anticipated for older patients, women, and those with
stroke or TIA prior to qualifying event, hypertension, and
diabetes. Observed baseline differences across sub-
groups may be important in the assessment of treatment
effects within these groups. Some of these are potential-
ly relevant confounders, such as the relationships between
older age and prior antiplatelet agent use, or between
global region and time from qualifying event to random-
ization, because those relationships within subgroups could
also be associated with outcome events. Others are sta-
tistically significant relationships that are unlikely to
confound a treatment effect, such as the apparent rela-
tionship between smoking and time from the qualifying
event, but nevertheless provide important descriptions
of the cohort. The relevance of these factors will need
to be weighed in the context of the overall and sub-
group analyses of treatment effects in NAVIGATE ESUS,
which are anticipated in the near future. Further, these
data will provide a robust opportunity to determine if
different ESUS subgroups have varying risks of recur-
rent stroke and other major vascular events. ESUS is a
broad definition and description of the full cohort across
multiple baseline characteristics helps to understand the
inherent heterogeneity and perhaps guide future trials about
optimal patient selection.
This study has potential limitations. Despite the large
size of NAVIGATE cohort, it represents patients who are
willing and able to participate in a clinical trial and there-
fore may be subject to limitations on generalizability, both
overall and within these subgroups. Differences in the
acute treatment of stroke and variations in risk factors
based on racial and genetic predispositions may intro-
duce heterogeneity among these subgroups. Further,
diagnostic testing may affect outcome analysis as pa-
tients in higher income countries may have undergone
more extensive pre-enrollment investigation than those
in middle or lower income countries.
NAVIGATE ESUS is the largest randomized trial in ESUS
and the first to address new paradigms for stroke diag-
nosis and prevention. The results, particularly in key
subgroups, are expected to shed new light on the treat-
ment and prognosis of ESUS.
Appendix: Supplementary Material
Supplementary data to this article can be found online
at doi:10.1016/j.jstrokecerebrovasdis.2018.01.027.
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